Trial Profile
An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms SENTINEL
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 01 Mar 2017 Status changed from recruiting to active, no longer recruiting.